Kromek Group plc (KRMKF) Q4 2026 Earnings Call Transcript

Kromek said its FY2027 revenue expectation is in line with broker consensus of £30.3 million. Management also reiterated its previously communicated ambition to reach £60 million in revenue, supporting a positive longer-term growth outlook. The update provides no reported earnings results or revised guidance beyond alignment with existing market expectations.

Analysis

The valuation hinge is not the reiterated FY27 revenue number but evidence that Kromek can convert its radiation-detection pipeline into repeatable, higher-margin production revenue. At this scale, even modest shipment or acceptance delays can shift a material portion of annual sales and push cash needs forward; therefore, quarterly order intake, backlog coverage, customer concentration, gross margin and operating-cash conversion matter more than management’s medium-term revenue aspiration. A revenue ramp without improving inventory turns and receivables would be a negative signal, indicating working-capital-funded growth rather than operating leverage.

Competitive read-through is mixed for MIR, OSIS and SMIN: Kromek’s commercial traction would validate specialized detector demand, but its small scale makes it more likely to be a niche supplier or acquisition target than a near-term share taker from larger security and radiation-monitoring incumbents. The contrarian risk is that consensus treats the stated outlook as de-risked despite public-sector/security procurement being milestone-driven and inherently lumpy. Over the next 1-3 months, the catalyst is contract, backlog and cash disclosures; over 6-18 months, the thesis requires demonstrable gross-margin expansion and reduced financing dependence, not simply top-line progress.

Key Decisions for Investors

• Do not establish a directional KMK position solely on reiterated guidance; treat it as a watch item until the next update discloses order-book coverage sufficient to support FY27 sales and positive evidence of cash conversion.
• For investors able to trade AIM liquidity, consider a small long KMK only after a contract award or interim results confirm both revenue visibility and stable/improving gross margin; target a 6-12 month holding period, with position sizing constrained by liquidity and financing risk.
• Use a failure trigger: exit or avoid the long if revenue guidance is cut, receivables/inventory materially outpace sales, or management signals additional equity funding before the revenue ramp is evidenced.
• Monitor MIR and OSIS as liquid sector read-throughs rather than direct shorts: broad radiation/security-budget acceleration would be more investable through these larger names, while Kromek-specific contract slippage would not necessarily impair their earnings.